AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04434651 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SPGB
Description: Sphenopalatine Ganglion Block using 2% lidocaine in block group. Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge a syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril SPGB using normal saline is performed in the control group
Study NCT01690624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858
Description: Monotherapy with BI 836858 administered as intravenous infusion
Study NCT03048968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gait, sit-to-stand movement, stair climbing and treadmill gait
Description: Spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system, surface electromyography (sEMG) and F-Scan Mobile system during 10m walking test. Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during stair climbing. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
Study NCT03048968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sit-to-stand movement and treadmill gait
Description: Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
Study NCT03048968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait enhancing mechatronic system (GEMS)
Description: Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS in elderly adults.~Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients.
Study NCT03048968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
Study NCT00136656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic
Description: cephalosporine by oral route : cefixime
Study NCT00136656 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: antibiotics
Description: cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
Study NCT03829982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to bright light during the day
Description: Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
Study NCT03829982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to dim light during the day
Description: Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
Study NCT03893799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: intravenous administration
Study NCT03158415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T1DToolkit.org mobile diabetes education
Description: Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults.
Study NCT00527267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
Study NCT00527267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 073
Description: 30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
Study NCT02674841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback on TUT
Description: Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
Study NCT02674841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No feedback on TUT
Description: Access only to live visual feedback on pulling force from an application on an iPad.
Study NCT02674841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
Study NCT02674841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
Study NCT02235298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.
Study NCT02235298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL
Study NCT02235298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL
Study NCT02235298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pill taken once daily to mimic Dapagliflozin
Study NCT00485693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 150 mg Bupivacaine HCl
Study NCT00485693 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SKY0402
Description: 600 mg SKY0402 (study drug)
Study NCT03565484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: susceptibility guided therapy
Description: Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.
Study NCT03565484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: personal medication history guided therapy
Description: Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
Study NCT03565484 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: personal medication history guided therapy
Description: Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
Study NCT03565484 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: salvage treatment for failed eradication
Description: If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
Study NCT01565187 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
Study NCT00973999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Description: Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.~Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle.
Study NCT04452383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + propofol
Description: effect of adding ketamine to propofol for patients undergoing DISE surgery
Study NCT04452383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: effect of IV propofol alone for patients undergoing DISE surgery
Study NCT03874169 — intervention group
Intervention type: DEVICE
Intervention: E4 wristband
Description: A biosensor watch that monitors the patient's heartbeat, heart rate variability, skin conductance, and temperature in order to discover if they are having a GI bleed
Study NCT01878305 — intervention group
Intervention type: DEVICE
Intervention: Molecular Adsorbent Recirculating System (MARS)
Description: MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
Study NCT03303534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ScandiShake
Description: weight gain supplement low in protein
Study NCT01911871 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: a blood sample was taken on the day of inclusion
Study NCT00012259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: troxacitabine
Study NCT02842957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
Study NCT00758550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® Toric IOL
Description: AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
Study NCT00758550 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof Natural
Description: AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
Study NCT00968695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
Study NCT01588093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Increlex
Description: Increlex 120 micrograms/kg body weight single subcutaneous injection
Study NCT01588093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
Study NCT00869934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavior Therapy
Description: Sleep restriction, stimulus control, cognitive therapy
Study NCT00869934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Description: Sleep restriction and stimulus control
Study NCT00869934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Cognitive restructuring therapy
Study NCT01830049 — intervention group
Intervention type: OTHER
Intervention: Take blood
Study NCT03188835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Diet
Description: A 2 weeks of hypercaloric diet supplemented with fructose or glucose
Study NCT03188835 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cold exposure
Description: Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
Study NCT00859404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oglemilast
Description: Tablet oglemilast or placebo once a day, for 12 weeks
Study NCT03188835 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 18FDG
Description: I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
Study NCT00083603 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Empty TBC-FPV
Description: Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
Study NCT03188835 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 11C-acetate
Description: i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
Study NCT03188835 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: [3-3H]-glucose
Description: i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
Study NCT00859404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oglemilast
Description: Tablet oglemilast or placebo once a day, for 12 weeks
Study NCT03188835 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [U-13C]-palmitate
Description: i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
Study NCT00083603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
Description: rMVA 10\^8 pfu /2mL administered in each deltoid
Study NCT00083603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
Description: rMVA 10\^9 pfu /2mL administered in each deltoid
Study NCT00083603 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TBC-MVA and TBC-FPV
Description: Empty MVA 10\^7 pfu/2mL administered into each deltoid
Study NCT00083603 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TBC-MVA and TBC-FPV
Description: Empty MVA 10\^8 pfu/2mL administered into each deltoid
Study NCT00083603 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TBC-MVA and TBC-FPV
Description: Empty MVA 10\^9 pfu/2mL administered into each deltoid
Study NCT02029157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ197
Study NCT02029157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02895828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise
Description: the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
Study NCT02895828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Strengthening Exercise
Description: the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
Study NCT01374269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
Study NCT01374269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID (Nonsteroidal anti-inflammatory drugs)
Description: The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
Study NCT02792699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 798
Description: Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
Study NCT02792699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABP 798
Description: Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
Study NCT02792699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (US)
Description: Supplied as a 10 mg/mL liquid concentrate for IV administration.
Study NCT02792699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (EU)
Description: Supplied as a 10 mg/mL liquid concentrate for IV administration.
Study NCT01807247 — intervention group
Intervention type: PROCEDURE
Intervention: Intensive lower limbs muscles strengthening
Study NCT02990780 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally fractionated concurrent chemo-radiotherapy
Description: 5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.
Study NCT02990780 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated hypofractionated concurrent chemo-radiotherapy
Description: 5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.
Study NCT01823601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Management Program
Description: Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
Study NCT01823601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seminars in Health
Description: Volunteers that participate in 10 weekly sessions of seminars in health
Study NCT03486366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non interventional trial
Description: other
Study NCT05976126 — intervention group
Intervention type: OTHER
Intervention: Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements
Description: Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.
Study NCT04228497 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gastric ultrasound
Description: Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.
Study NCT04228497 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: gastric ultrasound
Description: Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.
Study NCT04228497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the clear fluid intake
Description: the clear fluid intake
Study NCT04228497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the clear fluid intake
Description: the clear fluid intake
Study NCT01589497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Participants with body weight \</= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight >50kg were administered one 600 mg tablet orally once daily.
Study NCT01589497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
Study NCT01589497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.